Research

Hormonal

Tirzepatide treatment significantly reduces the prevalence of metabolic syndrome in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

If you have type 2 diabetes, tirzepatide (a once-weekly injection) is highly effective at reducing the cluster of risk factors that make up metabolic syndrome (like high blood sugar, high blood pressure, and high triglycerides). It works better than standard insulin or other common diabetes medications in clinical trials. While lifestyle changes are important, they are often not enough on their own to resolve metabolic syndrome, making this medication a powerful tool for improving your cardiovascular risk profile.

GoodSupportsHIGH confidence
Reductions in the prevalence of patients meeting the criteria for metabolic syndrome was significantly greater with all tirzepatide doses versus placebo, semaglutide 1 mg, insulin glargine, and insulin degludec (p < 0.001).
Stephen J. Nicholls et al. · Cardiovascular Diabetology · 2024

Why this rating

Post hoc analysis of multiple Phase 3 RCTs (SURPASS 1-5).

Source

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program

Stephen J. Nicholls et al. · Cardiovascular Diabetology · 2024

DOI 10.1186/s12933-024-02147-9

rct · n=5219Cited 10×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →